Epithalon (Epitalon) — Telomerase Activator Peptide — Peptides
Tetrapeptide bioregulator studied for telomerase activation and anti-aging. Russian research. Animal data primarily.
Overview
Epithalon (Epitalon, Epithalone) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Professor Vladimir Khavinson at the Institute of Bioregulation and Gerontology in St. Petersburg, Russia. It is the synthetic version of epithalamin, a peptide extract from the pineal gland. Epithalon's primary mechanism of interest is telomerase activation: in cell culture studies, epithalon induced telomerase activity in human somatic cells, elongated telomeres, and extended the replicative lifespan of fibroblasts beyond the Hayflick limit. Khavinson's group published over 100 papers on epithalon and related peptide bioregulators, reporting lifespan extension in animal models (mice, rats, and Drosophila), improved melatonin secretion, restored circadian rhythms, and anti-aging effects on multiple organ systems. In a notable longitudinal study, elderly patients treated with epithalamin (the crude pineal extract) showed reduced mortality over a 6-year follow-up compared to controls. However, these studies have been criticized for methodological limitations, small sample sizes, and limited independent replication outside of Russian research groups. Epithalon has not been subject to rigorous Western clinical trials, and the telomerase activation claims require independent verification. It is available as a research peptide and is used in the anti-aging community, typically administered as a subcutaneous injection course.
Indications
- Investigational: Telomere lengthening and anti-aging (Russian research)
- Investigational: Circadian rhythm restoration and melatonin optimization
- Research only: Cellular senescence prevention
Mechanism of Action
Epithalon activates telomerase reverse transcriptase (hTERT), the catalytic subunit responsible for adding telomeric repeats to chromosome ends
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Epithalon | 5-10 mg | Once daily x 10-20 days | Standard Khavinson protocol — course-based dosing |
| Epithalon | 5 mg | Once daily x 10 days, repeated every 6 months | Periodic course protocol used in anti-aging community |
Evidence Grade
GRADE D
Safety & Contraindications
- Limited human safety data — primarily Russian clinical data
- Telomerase activation theoretical concern: could promote cancer in cells with oncogenic mutations
- No Western clinical trials for independent validation
- Injection site reactions possible
- Research peptide only — quality varies between suppliers
- Small study sizes in published human research